Marshall Wace’s Lexeo Therapeutics LXEO Stock Holding History

Marshall Wace’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-81,009	Closed	-$281K	–	2965
2025 Q1	$281K	Buy	81,009 +63,215	+355%	+$280K	﹤0.01%	2295
2024 Q4	$117K	Buy	+17,794	New	+$140K	﹤0.01%	2426

Other funds holding LXEO

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace's LXEO Position: Q2 2025 in Review

Marshall Wace sold out of Lexeo Therapeutics (LXEO) in Q2 2025, closing a stake of 81,009 shares — an estimated $281K sold.

Marshall Wace first reported a position in LXEO in Q4 2024 and held it in 2 quarters. The position peaked at $281K in Q1 2025. 90 funds tracked by Wall St. Rank hold LXEO as of Q2 2025.

Marshall Wace reported no remaining Lexeo Therapeutics position as of Q2 2025 after selling out during the quarter.
Marshall Wace sold 81,009 Lexeo Therapeutics shares in Q2 2025, an estimated $281K.
Marshall Wace first reported a position in Lexeo Therapeutics in Q4 2024 and held it in 2 quarters.
Marshall Wace's Lexeo Therapeutics position peaked at $281K in Q1 2025.
90 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2025.

Based on Marshall Wace's 13F filing for Q2 2025, filed 13 Aug 2025.